Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in affluent countries. It may progress to cirrhosis and liver cancer. At present, there is no approved drug for NAFLD. Although healthy diet and exercise is often recommended, there is little supportive evidence. Therefore, the investigators plan to conduct a randomized controlled trial comparing a low glycemic index dietary intervention program and simple lifestyle advice in NAFLD patients. The primary endpoint is resolution of NAFLD. Non-invasive tests will be used to assess the study subjects. Proton-magnetic resonance spectroscopy is used to quantify hepatic triglyceride content, and transient elastography is used to quantify liver fibrosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
159
The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital
Hong Kong SAR, China
Resolution of NAFLD by proton-magnetic resonance spectroscopy
Time frame: Month 12
Partial resolution of NAFLD
Time frame: Month 12
Visceral fat measurement
Time frame: Month 12
Liver fibrosis by transient elastography
Time frame: Month 12
Metabolic endpoints
Time frame: Month 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.